Wall Street Zen Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold

Turn Therapeutics (NASDAQ:TTRX) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Other analysts have also issued reports about the stock. D. Boral Capital reiterated a “buy” rating and set a $8.00 price target on shares of Turn Therapeutics in a research note on Tuesday, March 24th. Weiss Ratings raised shares of Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

Turn Therapeutics Stock Performance

Shares of NASDAQ TTRX opened at $9.12 on Friday. The company has a current ratio of 2.23, a quick ratio of 2.23 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $271.68 million and a PE ratio of -48.00. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50. The stock has a fifty day simple moving average of $6.34 and a 200-day simple moving average of $4.68.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of Turn Therapeutics

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in shares of Turn Therapeutics in the 4th quarter valued at about $99,000. Millennium Management LLC purchased a new stake in Turn Therapeutics during the fourth quarter worth approximately $377,000. Jane Street Group LLC purchased a new stake in Turn Therapeutics during the fourth quarter worth approximately $68,000. Brown Brothers Harriman & Co. acquired a new position in Turn Therapeutics in the fourth quarter valued at approximately $93,000. Finally, LPL Financial LLC acquired a new position in Turn Therapeutics in the fourth quarter valued at approximately $51,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.